X4 Pharmaceuticals, Inc — Director's Dealing 2022

Nov 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: X4 Pharmaceuticals, Inc (XFOR)
CIK: 0001501697
Period of Report: 2022-11-07

Reporting Person: Ragan Paula (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-07	Stock Appreciation Right	$1.8	A	3438335	Acquired	2032-11-07	Common Stock (3438335.0)	Direct

Footnotes

F1: The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of November 7, 2022, subject to the Reporting Person remaining an employee of the Issuer through and including each applicable vesting date.